Celgene Corp. (CELG) announced Thursday morning that its subsidiary, Celgene International Sàrl, has decided to withdraw the new indication submission to the Committee for Medicinal Products for Human Use for REVLIMID.
Celgene also reaffirmed its guidance for the full years 2012 and 2015.
Celgene gapped open sharply lower Thursday and is now down 8.46 at $58.70 on above average volume. The stock has dropped to over a 9-month low.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.